Declaration of competing financial interests
From the following article:
Leukotriene modifiers as potential therapeutics for cardiovascular disease
Colin D. Funk
Nature Reviews Drug Discovery 4, 664-672 (August 2005)
doi:10.1038/nrd1796
Declaration: C.D.F. receives research funding from Merck & Co. and consulting fees from Critical Therapeutics Inc.
